Bio-Techne (TECH) Proxy filing summary

Executive summary

• A special meeting is scheduled for September 23, 2026, for shareholders to vote on the proposed acquisition by Merck KGaA at $73.00 per share in cash, making the company a wholly-owned subsidiary and delisting its stock from Nasdaq.

• The board unanimously recommends approval, citing a 24–43% premium over recent trading prices and a thorough strategic review, including outreach to other potential bidders.

• If the merger is not completed, the company will remain public, but the stock price may decline, and termination fees may apply.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) approval of the merger agreement, (2) a non-binding advisory vote on executive compensation related to the merger, and (3) a proposal to adjourn the meeting if more votes are needed.

• Approval of the merger requires a majority of outstanding shares; abstentions and non-votes count as against.

• Dissenters' rights are available for shareholders who do not vote in favor and follow statutory procedures.

Board of directors and corporate governance

• The board conducted a multi-month process, including negotiations with multiple parties and financial advisors, and considered strategic alternatives.

• The board's recommendation is based on financial, strategic, and market factors, and the fairness opinion of Goldman Sachs.